One hundred fifty patients with potentially life-threatening digitalis toxicity were treated with digoxin-specific antibody fragments (Fab) purified from immunoglobulin G produced in sheep. The dose of Fab fragments was equal to the amount of digoxin or digitoxin in the patient's body as estimated from medical histories or determinations of serum digoxin or digitoxin concentrations. The youngest patient received Fab fragments within several hours of birth, and the oldest patient was 94 years old. Seventy-five patients (50%) were receiving long-term digitalis therapy, 15 (10%) had taken a large overdose of digitalis accidentally, and 59 (39%) had ingested an overdose of digitalis with suicidal intent. The clinical response to Fab was unspecified in two cases, leaving 148 patients who could be evaluated. One hundred nineteen patients (80%) had resolution of all signs and symptoms of digitalis toxicity, 14 (10%) improved, and 15 (10%) showed no response. After termination of the Fab infusion, the median time to initial response was 19 minutes, and 75% of the patients had some evidence of a response by 60 minutes. There were only 14 patients with adverse events considered to possibly or probably have been caused by Fab; the most common events were rapid development of hypokalemia and exacerbation of congestive heart failure. No allergic reactions were identified in response to Fab treatment. Of patients who experienced cardiac arrest as a manifestation of digitalis toxicity, 54% survived hospitalization. Reasons for partial responses and nonresponses, in descending order of frequency, were underlying heart disease that was the true cause of some of the presumed manifestations of suspected digitalis toxicity, too low a dose of Fab, and treatment of patients who were already moribund. Thus, a treatment response can be expected in at least 90% of patients with solid evidence of advanced and potentially life-threatening digitalis toxicity. (Circulation 1990;81:1744-1752 
Based on several such favorable responses, a multicenter clinical trial using purified digoxinspecific Fab fragments was initiated. Interim reports were published when 26 and 63 patients had been enrolled2,3; the present report is the summary of this prospective multicenter study of 150 patients with life-threatening digitalis intoxication who were treated with purified digoxin-specific Fab fragments.
Methods
Preparation of Punified Fab Fragments of Digoxin-Specific Antibodies
As described previously, sheep were immunized with a digoxin-serum albumin conjugate and antisera were collected from animals that responded with high titers of antibody with high affinity and specificity for digoxin.4-6 Intact antibody was cleaved with papain, yielding digoxin-specific Fab fragments.5i7 The Fab fragments were isolated and purified by passing the papain digest through an affinity chromatography step.5 The final purified Fab fragments were determined to be both sterile and pyrogen free by standard tests, and the material was then lyophilized in 40-mg aliquots. Of the 150 patients, 107 (71%) survived to hospital discharge. Of the 43 who died, 20 had complete resolution of toxicity, 12 had improvement in signs of toxicity, and 11 had no response to Fab. The majority of the 43 deaths could be ascribed to underlying heart disease still present after resolution of digitalis toxicity or to other medical illnesses. Of the patients who were moribund before treatment with Fab fragments, the majority ultimately died of the consequences of neurologic and cardiovascular complications of their protracted pretreatment cardiac arrest or low output status. However, several of these patients demonstrated remarkable resolution of both their digitalis toxicity and their apparently moribund state. Notably, of the 56 patients whose digitalis toxicity culminated in cardiac arrest, 30 (54%) survived hospitalization after treatment with Fab fragments.
Laboratory Evidence of Response to Fab Fragments
A dramatic fall in serum potassium concentration can occur after reversal of severe digitalis toxicity because reversal of Na,K-ATPase inhibition tends to reestablish rapidly the normal transmembrane potassium gradient. Serum potassium concentrations before and 2 and 6 hours after treatment were available in 82 cases and indicated a significant reduction from a median of 5.0 to 4.1 meq/l (p=0.0001). This reduction occurred despite concomitant administration of potassium chloride in some cases. The time course of decline in serum potassium concentration was consistent with the rapid time course of arrhythmia response; that is, declines in serum potassium were often noted within 1 hour and appeared complete within 4 hours (Figure 3 ).
Adverse Responses to Treatment With Digoxin-Specific Fab Fragments
Adverse events related to Fab administration were initially raised as a possibility in 32 of the 150 patients. In only 14 of these 32 patients were the reported adverse events judged to be possibly or probably caused by Fab. Relatively rapid development of hypokalemia was observed in six of the 150 patients (4%). Four patients (3%) experienced exacerbations of congestive heart failure after Fab treatment; this was thought possibly to have been caused by loss of inotropic support from digitalis therapy. However, because many patients with poor ventricular function also received multiple other treatments, it is not possible to determine a true incidence of The dominant pattern of serial serum creatinine measurements was one of stable or improved renal function after Fab therapy. Three patients with pretreatment serum creatinine levels in the normal range had posttreatment values of 1.5 mg/dl or more. In all three cases, the rise in serum creatinine was clearly ascribable to decreased renal perfusion before Fab. One patient was described as oliguric, and the other two had cardiac arrests before Fab treatment.
Serum Digoxin Measurements After Fab Treatment
Laboratory evidence for the binding of digoxin or digitoxin by the Fab fragments was available in the posttreatment serum drug concentrations in 11 patients studied early in the trial. In all cases, the concentration of free, pharmacologically active digoxin or digitoxin in the serum fell to near-0 levels within 1-2 minutes of administration of Fab fragments. The total serum digoxin concentration, reflecting pharmacologically inactive antibody-bound drug, rose rapidly to values 10-to 20-fold those before treatment (Figure 4) . Equilibrium dialysis or ultrafiltration are required to measure the free digoxin concentration after treatment because in a patient's serum, Fab 4 . Flow diagram illustrating temporal relations between recorded cardiac rhythms, ingestion of suicidal overdose of digoxin (19 mg), and results of treatment with digoxin-specific Fab fragments. The patient is a 60-year-old woman with a history of rheumatic heart disease and atrial fibrillation (AF). About 26 hours after her suicidal ingestion, she developed atrioventricular junctional rhythm (AVJR); later, she developed fascicular tachycardia (Figure 2 ) that was initially mistaken for supraventricular tachycardia (SVT). After treatment with Fab fragments, there is abrupt rise in total serum digoxin concentrations but a fall in free serum digoxin concentrations (determined by radioimmunoassay after equilibrium dialysis). CHB, complete heart block.
Reproduced with permission.20 cardiac glycoside effects in experimental models extending from isolated membrane Na,K-ATPase preparations to intact animals, it was predicted nearly two decades ago that an immunochemical approach might be clinically successful in reversing digitalis toxicity.5,14-16 The advantages of the smaller size of the Fab fragment (molecular weight, 50,000) include a more rapid onset of action due to enhanced diffusion into the interstitial space and, in patients with normal renal function, relatively rapid clearance of digoxin bound to Fab fragments in the urine (half-life, 16 
